Illumina/ILMN

$116.67

-0.02%
-
1D1W1MYTD1YMAX

About Illumina

Illumina, Inc. is a provider of sequencing and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.

Ticker

ILMN

Sector

Healthcare

Trading on

NASDAQ

Industry

Scientific & Technical Instr.

CEO

Jacob Thaysen

Employees

10,590

Headquarters

San diego, United States

Illumina Metrics

BasicAdvanced
$18.84B
Market cap
-
P/E ratio
-$7.34
EPS
1.21
Beta
-
Dividend rate
$18.84B
1.21339
$232.23
$89.00
1.69M
1.662
1.288
25.918
25.918
-10.37%
-18.79%
-12.87%
4.183
3.274
91.006
66.803
-1.72%
73.83%
11.62%

What the Analysts think about Illumina

Analyst Ratings

Majority rating from 24 analysts.
Hold

Price Targets

Average projection from 21 analysts.
32.53% upside
High $253.00
Low $100.00
$116.67
Current price
$154.62
Average price target

Illumina Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-15.59% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.12B
0.27%
Net income
$-175M
-76.79%
Profit margin
-15.59%
-76.86%

Illumina Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 685.94%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.08
$0.32
$0.33
$0.14
-
Expected
$0.03
$0.02
$0.12
$0.02
$0.04
Surprise
215.79%
1,636.39%
167.61%
685.94%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Illumina stock?

Illumina (ILMN) has a market cap of $18.84B as of April 20, 2024.

What is the P/E ratio for Illumina stock?

The price to earnings (P/E) ratio for Illumina (ILMN) stock is 0 as of April 20, 2024.

Does Illumina stock pay dividends?

No, Illumina (ILMN) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Illumina dividend payment date?

Illumina (ILMN) stock does not pay dividends to its shareholders.

What is the beta indicator for Illumina?

Illumina (ILMN) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Illumina stock price target?

The target price for Illumina (ILMN) stock is $154.62, which is 31.67% above the current price of $117.43. This is an average based on projections from 21 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Illumina stock

Buy or sell Illumina stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing